Abstract:Alzheimer's disease (AD) is a devastating disease characterized by synaptic and neuronal loss in the elderly. Compelling evidence suggests that soluble amyloid-β peptide (Aβ) oligomers induce synaptic loss in AD. Aβ-induced synaptic dysfunction is dependent on overstimulation of N-methyl-D-aspartate receptors (NMDARs) resulting in aberrant activation of redox-mediated events as well as elevation of cytoplasmic Ca2+, which in turn triggers downstream pathways involving phospho-tau (p-tau), caspases, Cdk5/dynamin-related protein 1 (Drp1), calcineurin/PP2B, PP2A, Gsk-3β, Fyn, cofilin, and CaMKII and causes endocytosis of AMPA receptors (AMPARs) as well as NMDARs. Dysfunction in these pathways leads to mitochondrial dysfunction, bioenergetic compromise and consequent synaptic dysfunction and loss, impaired long-term potentiation (LTP), and cognitive decline. Evidence also suggests that Aβ may, at least in part, mediate these events by causing an aberrant rise in extrasynaptic glutamate levels by inhibiting glutamate uptake or triggering glutamate release from glial cells. Consequent extrasynaptic NMDAR (eNMDAR) overstimulation then results in synaptic dysfunction via the aforementioned pathways. Consistent with this model of Aβ-induced synaptic loss, Aβ synaptic toxicity can be partially ameliorated by the NMDAR antagonists (such as memantine and NitroMemantine). PSD-95, an important scaffolding protein that regulates synaptic distribution and activity of both NMDA and AMPA receptors, is also functionally disrupted by Aβ. PSD-95 dysregulation is likely an important intermediate step in the pathological cascade of events caused by Aβ. In summary, Aβ-induced synaptic dysfunction is a complicated process involving multiple pathways, components and biological events, and their underlying mechanisms, albeit as yet incompletely understood, may offer hope for new therapeutic avenues.

Amyloid β: linking synaptic plasticity failure to memory disruption in Alzheimer's disease.

Amyloid Β: Linking Synaptic Plasticity Failure to Memory Disruption in Alzheimer’s Disease

Progress in molecular mechanisms of β-amyloid peptides in alzheimer's disease

Role of Amyloid Β Protein Receptors in Mediating Synaptic Plasticity.

The Intersection of Amyloid Beta and Tau at Synapses in Alzheimer’s Disease

Oligomeric Aβ-induced Synaptic Dysfunction in Alzheimer’s Disease

The role of pathological tau in synaptic dysfunction in Alzheimer’s diseases

A mechanistic hypothesis for the impairment of synaptic plasticity by soluble Aβ oligomers from Alzheimer’s brain

Targeting epigenetic mechanisms in amyloid-β-mediated Alzheimer's pathophysiology: unveiling therapeutic potential

Targeting Synaptic Pathology in Alzheimer’s Disease

Gene expression parallels synaptic excitability and plasticity changes in Alzheimer’s disease

A Molecular Communication Perspective of Alzheimer's Disease: Impact of Amyloid Beta Oligomers on Glutamate Diffusion in the Synaptic Cleft

Altered synaptic plasticity at hippocampal CA1-CA3 synapses in Alzheimer's disease: integration of amyloid precursor protein intracellular domain and amyloid beta effects into computational models

Dysregulation of Neuronal Protein Synthesis in Alzheimer’s Disease

Aβ induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss

Novel crosstalk mechanisms between GluA3 and Epac2 in synaptic plasticity and memory in Alzheimer's disease

Role of APP and Aβ in Synaptic Physiology.

Dysfunction of NMDA receptors in Alzheimer’s disease

Overview of the Molecular Modalities and Signaling Pathways Intersecting with β-Amyloid and Tau Protein in Alzheimer’s Disease

The Role of Intracellular Amyloid Beta in Alzheimer'S Disease

N-Methyl-<i>D</i>-Aspartate Receptors Mediate Excitotoxicity in Amyloid Beta-Induced Synaptic Pathology of Alzheimer’s Disease